Meridian Life Science, Inc.
5171 Wilfong Road
About Meridian Life Science, Inc.
Meridian Bioscience is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and biopharmaceutical enabling technologies that help deliver answers. Our products provide accuracy, simplicity and speed for the early diagnosis and treatment of common medical conditions, such as C. difficile, H. pylori., foodborne diseases. and respiratory infections.
For more than 30 years, Meridian Bioscience, Inc., has established a proven track record of profitable growth and product launches designed to enhance patient well being while reducing the total outcome costs of healthcare. Meridian diagnostic products are used outside of the human body and require little or no special equipment.
We maintain market leadership by responding to emerging diseases and changing medical needs. Since 1991, Meridian has developed and introduced more than 56 innovative products. Meridian also grows through acquisition, licensing, or supply agreements that have added almost 100 new products to our catalog.
Meridian has strong market positions in the areas of gastrointestinal infections, serology, parasitology and fungal disease diagnosis. We actively market our products to hospitals, reference laboratories, research centers, physician offices and diagnostics manufacturers in more than 60 countries around the world.
Our shares are traded on the NASDAQ National Market, symbol VIVO.
192 articles with Meridian Life Science, Inc.
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced the launch of its new Air-Dryable™ Direct DNA qPCR Plant Mix.
Meridian Bioscience, Inc., a provider of diagnostic testing solutions and life science raw materials, announced its participation in the H.C. Wainwright Global Life Sciences 2021 Virtual Conference.
Meridian Bioscience, Inc., a provider of diagnostic testing solutions and life science raw materials, provided a further update on its application for Emergency Use Authorization with the U.S. Food and Drug Administration for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform.
Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has developed a series of innovative and high performing master mixes designed for manufacturing room-temperature stable molecular diagnostic assays that do not require lyophilization.
Meridian launches a novel SARS-CoV-2 antibody pair designed for developing highly sensitive rapid antigen tests from saliva samples
Meridian Bioscience, Inc., a leading provider of diagnostic testing solutions and life science critical raw materials, is pleased to announce the launch of a novel highly sensitive SARS-CoV-2 antibody pair to the trimeric spike protein to accelerate development of COVID-19 assays from patient saliva.
Meridian Bioscience, Inc. announced that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the 40th Annual William Blair Growth Stock Conference on Tuesday, June 9, 2020 at 8:40 AM CT.
Meridian Bioscience Announces It Will Supply Reagents for the Manufacturing of Tens of Millions of COVID-19 Antibody Tests Per Month
Meridian Bioscience, Inc. announced that its SARS-CoV-2 antigens and related reagents are part of assays granted U.S. Food and Drug Administration Emergency Use Authorization, with projected production schedules of tens of millions of COVID-19 antibody tests per month.
Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter 2020 financial results Friday, May 8, 2020
Meridian Bioscience, Inc. (NASDAQ: VIVO), announced today the launch of several novel recombinant antigens critical for the development of antibody tests for COVID-19. Since the emergence of COVID-19 outbreaks in January, Meridian has supported molecular diagnostic companies with critical master mixes and enzymes for their COVID-19 Molecular Diagnostics tests. To meet the massive need for antibody testing, Meridian has now launched a series of
Meridian Bioscience Announces better-than-expected Preliminary Second Quarter Fiscal 2020 Revenue Results With Double-digit Growth
Meridian Bioscience, Inc., a provider of diagnostic testing solutions and life science raw materials, provided a business update including preliminary revenue results for its second quarter of fiscal 2020.
Meridian Bioscience Supports Diagnostic Companies in Fighting Coronavirus Pandemic by Providing Zero Cost Proprietary Technology for Evaluation
Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its increased commitment to the global fight against COVID-19 by making available zero cost samples of the company’s proprietary technologies to developers and manufacturers of molecular assays for COVID-19 detection
Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of immunoassay, molecular, and blood chemistry diagnostic testing solutions, today announced that it has received FDA-clearance for Meridian’s new Curian™ and Curian™ HpSA® assay.
Meridian’s Novel Air-Dryable qPCR Mix Decreases Costs and Simplifies Workflows for Molecular Test Manufacturers
Meridian Bioscience, Inc. (NASDAQ: VIVO), following the extremely successful launch of the Lyo-Ready qPCR mixes, is proud to introduce today its Air-Dryable qPCR Mix.
Meridian Bioscience Signs Definitive Agreement to Acquire Exalenz Bioscience; Adds State-Of-The-Art Urea Breath Test Diagnostics Platform
Meridian Bioscience, Inc. (NASDAQ: VIVO) and Exalenz Bioscience Ltd. (TASE: EXEN) announced today that the two companies have entered into a definitive agreement for Meridian to acquire Exalenz for ₪6.10 per share in cash with an implied transaction value of approximately $49 million.
CINCINNATI, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2019. First Quarter Fiscal 2020 Highlights: Diagnostics segment delivered nearly $35 million in revenues; fourth consecutive quarter above $33 million, signaling continued stabilization of this business; Positive customer feedback for our revogene™ molecular diagnostics system continues to build; Diagnostics segment new product
Meridian Bioscience Lyo-Ready 1-Step RT-qPCR Mix is Used in the Development of Molecular Diagnostics for New Coronavirus Outbreak
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced a novel coronavirus, identified by Chinese authorities on January 7 and currently named 2019-nCoV, is a new strain that had not been previously identified in humans
Meridian Launched a New High-Fidelity Polymerase to Offer Robust Amplification for NGS and PCR Applications
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity amplification, but also offers market-leading amplification for companion diagnostic (CDx) and clinical testing.
Meridian Bioscience to Hold First Quarter 2020 Financial Results Conference Call on February 7, 2020
Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions.
Meridian Bioscience Reports Fourth Quarter and Full-Year Fiscal 2019 Operating Results and Provides Fiscal 2020 Guidance
Meridian Bioscience, Inc. announced financial results for the fourth quarter and fiscal year ended September 30, 2019.
Meridian Bioscience, Inc. announced that it has submitted Curian™ and the Curian™ HpSA assay to the FDA for review.